Tag: Vaxxas
Vaxxas hits enrollment target in trial of HD-MAP technology for pandemic response
Australian biotechnology company Vaxxas has completed enrollment for its largest clinical trial to date, testing the safety and immune response of its high-density microarray patch (HD-MAP) for vaccine delivery.
Vaxxas secures $2M grant from BARDA to develop needle-free mRNA vaccines
Vaxxas, a clinical-stage biotechnology company specializing in high-density microarray patch (HD-MAP) vaccine delivery, has been awarded a $2 million (AUD 3.2 million) grant as a Concept Stage winner in the United States Biomedical Advanced Research and Development Authority’s (BARDA) $50 million Patch Forward Prize.
Vaxxas to develop first room-temperature stable RSV vaccine with NIH license
Vaxxas, a clinical-stage biotechnology company known for its innovative high-density microarray patch (HD-MAP) vaccination platform, has secured a worldwide license from the United States National Institutes of Health (NIH) for a next-generation vaccine antigen aimed at combating Respiratory Syncytial Virus (RSV).
Vaxxas’ new needle-free vaccine manufacturing plant opens in Queensland
Biotechnology company Vaxxas has completed work on its new needle-free vaccine technology manufacturing facility in Northshore Hamilton.
Vaxxas unveils positive clinical trial results for needle-free COVID-19 vaccine
Australia biotechnology company Vaxxas said it achieved positive interim results from a Phase I human clinical trial with the first needle-free COVID-19 vaccine candidate.
University of Sydney’s industry collabs win CRC-P funding
Two projects involving medical and scientific researchers from the University of Sydney have secured government funding through the Cooperative Research Centres Projects’ (CRC-P) latest round.
Vaxxas’ needle-free seasonal influenza vaccine enters clinical trial
Vaxxas has commenced the Phase I clinical trial of the first needle-free inactivated seasonal influenza vaccine quadrivalent (IIV4) candidate via its proprietary high-density microarray patch (HD-MAP) technology.
Vaxxas raises $34 million to clinically advance needle-free vaccines, including a next-generation COVID-19 vaccine...
Vaxxas, a clinical-stage biotechnology company commercializing a novel vaccination platform, has announced it has completed a financing round which raised US$23 million (A$34 million) in new funds.
Vaxxas kickstarts needle-free COVID-19 vaccine clinical trial
Australian biotechnology company Vaxxas has begun the Phase I clinical trial of the first needle-free COVID-19 vaccine candidate.
Vaxxas receives $8.2 million Commonwealth Government grant to support manufacturing scale-up in its Australian...
Media Release by Vaxxas
Vaxxas will receive an AU$8.2 million second-round grant as part of the Commonwealth Government’s Modern Manufacturing Initiative (MMI) to support the...
Featured Article
Circular beds: Revolutionising sustainable bedding in Australia
A new wave of innovation is transforming the Australian manufacturing sector, with sustainability at its core. ROBOVOID, in collaboration with Swinburne University, GT Recycling, and Sustainability Victoria, has developed a groundbreaking bed base made entirely from recycled plastic.
